Hepatitis Progress Too Slow, Deaths Persist
Fewer than five percent of people with chronic hepatitis B are receiving treatment, despite effective vaccines and cures.
Updated on Nov. 2, 2026 in COVID-19

Live Poll
Do you trust your local health system to provide hepatitis testing and treatment?
The World Health Organization reports that progress toward eliminating viral hepatitis is too slow, with hepatitis B and C claiming 1.34 million lives in 2024. Most people living with these chronic infections remain undiagnosed or untreated, and the situation affects readers worldwide.
Why it matters
Viral hepatitis B and C cause 95 percent of hepatitis-related deaths worldwide, and the gap between available prevention and treatment and who actually receives them is wide. The WHO's Global Hepatitis Report 2026 frames stigma, weak health systems and inequitable access to care as the main reasons many people remain untreated.
The figures come from WHO global estimates published in the Global Hepatitis Report 2026, comparing 2024 burden against a 2015 baseline. Treatment coverage is markedly low, with only 20 percent of people with hepatitis C treated since 2015, and the report does not detail every regional breakdown.
The players
World Health Organization
The United Nations agency that leads global public health guidance and tracks viral hepatitis burden and elimination progress worldwide.
The details
The hepatitis B vaccine protects more than 95 percent of recipients against acute and chronic infection, yet only 17 percent of African babies received the birth dose in 2024. Hepatitis C can be cured in more than 95 percent of cases with a short course of curative therapy lasting eight to 12 weeks, but access remains limited. Progress has been made in some countries: Britain, Egypt, Georgia and Rwanda have shown that hepatitis can be eliminated as a public health problem.
Timeline
2015: baseline year against which infection and treatment declines are measured
2024: year of 1.34 million hepatitis deaths and 287 million chronic cases
2026: WHO released the Global Hepatitis Report 2026
Health Landscape
Measured against the 2015 baseline, the WHO reports a 32 percent drop in new hepatitis B infections, yet treatment coverage remains very low, with fewer than five percent of people with chronic hepatitis B receiving care. The gap between proven tools such as vaccines and cure therapies and their actual reach defines the current landscape for elimination.
Adults who have never been tested for hepatitis B or C may want to ask their doctor whether screening is appropriate. Routine vaccination against hepatitis B is worth confirming for people who may not have completed the series.
The takeaway
Hepatitis B and C remain major killers, yet effective vaccines and cure therapies already exist, so the main gap is testing and access. Ask your doctor whether hepatitis screening and vaccination make sense for you.
Further reading
For broader context on infectious disease response, explore our COVID-19 coverage.
Source note: This article includes information reported by جريدة الأهرام.
Live Poll
Do you trust your local health system to provide hepatitis testing and treatment?


